Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Miguel Sampayo"'
Autor:
José Enrique Alés-Martínez, Judith Balmaña, Pedro Sánchez-Rovira, Francisco Javier Salvador Bofill, Jose Ángel García Sáenz, Isabel Pimentel, Serafín Morales, María Fernández-Abad, Ainhara Lahuerta Martínez, Neus Ferrer, Pilar Zamora, Begoña Bermejo, Tamara Díaz-Redondo, María Helena López-Ceballos, María Galán, Jhudit Pérez-Escuredo, Laura Calabuig, Miguel Sampayo, José Manuel Pérez-Garcia, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 77, Iss , Pp 103780- (2024)
Purpose: To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal BRCA mutations (gBRCAm). Methods: OPHELIA (NCT03931551) was a single-arm, open-label
Externí odkaz:
https://doaj.org/article/19f49dc9a9694e038d227468d5e24fe9
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Antonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, Pablo Tolosa, Salvador Blanch, Adela Fernández-Ortega, Ander Urruticoechea, Isabel Blancas, Cristina Saura, Beatriz Rojas, Begoña Bermejo, José Ponce Lorenzo, María Gion, Patricia Cortez-Castedo, Elisenda Llabres, Elena Galve, Juan Fernando Cueva, Ana López, José Luis Alonso-Romero, Santiago González-Santiago, Eduardo Martínez de Dueñas, Eva Ciruelos, Griselda Martrat, Petra Gener, Daniel Alcalá-López, Miguel Sampayo-Cordero, Fernando Gómez-Peralta, Javier Cortés
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102520- (2024)
Summary: Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2−/PIK3CA-mutated advan
Externí odkaz:
https://doaj.org/article/c5ba8bd9a6864624b463e00529accd71
Autor:
Matilde Sánchez-Conde, Pilar Vizcarra, José Manuel Pérez-García, María Gion, María Pilar Martialay, Javier Taboada, Alberto Alonso-Fernández, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De La Torre, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
International Journal of Infectious Diseases, Vol 123, Iss , Pp 97-103 (2022)
Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- inter
Externí odkaz:
https://doaj.org/article/03300a66cee940b7bc9b769d46d85504
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Andrea Malfettone, Elena López-Miranda, María Gion, Elena Abad, Daniel Alcalá-López, Jhudit Pérez-Escuredo, José Manuel Pérez-García, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
De-escalation trials in oncology evaluate therapies that aim to improve the quality of life of patients with low-risk cancer by avoiding overtreatment. Non-inferiority randomized trials are commonly used to investigate de-intensified regimens with si
Externí odkaz:
https://doaj.org/article/4129d5abe3b54a4aa1163a0967a18f28
Autor:
Andrea Malfettone, Serena Di Cosimo, José Manuel Pérez-García, Alicia García, Miguel Sampayo-Cordero, Leonardo Mina, Carolina Herrero, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-3 (2021)
In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical
Externí odkaz:
https://doaj.org/article/33b48eb9a9dd438c9f6dd121fdf66906
Autor:
María Gion, José Manuel Pérez-García, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Javier Cortés, Andrea Malfettone
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials based on adequate outcomes such as disease-free survival and overall survival. Improvements in long-term outcomes have made it more
Externí odkaz:
https://doaj.org/article/8b548ce9bba54c9ca2cb0709f0aef8b1
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Andrea Malfettone, José Manuel Pérez-García, Antonio Llombart-Cussac, Javier Cortés, Almudena Pardo, Jordi Pérez-López
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Nonrandomized studies are usually excluded from systematic reviews. This could lead to loss of a considerable amount of information on rare diseases. In this article, we explore the impact of excluding nonrandomized studies on the generalizability of
Externí odkaz:
https://doaj.org/article/9f4d7fc64b8344aa8a9954194506836c
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Almudena Pardo-Mateos, Andrea Malfettone, José Pérez-García, Antonio Llombart-Cussac, Javier Cortés, Marc Moltó-Abad, Cecilia Muñoz-Delgado, Marta Pérez-Quintana, Jordi Pérez-López
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 14, Iss 1, Pp 1-11 (2019)
Abstract Background A preliminary exploratory study shows solid agreement between the results of case reports and clinical study meta-analyses in mucopolysaccharidosis Type I (MPS-I) adult patients. The aim of the present study is to confirm previous
Externí odkaz:
https://doaj.org/article/9855a7d39b014bba9957133dc07f8cb6
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, José Pérez-García, David Páez, Ángel L. Guerrero-Zotano, Javier Garde-Noguera, Elena Aguirre, Esther Holgado, Elena López-Miranda, Xin Huang, Andrea Malfettone, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
Contemporary Clinical Trials Communications, Vol 20, Iss , Pp 100678- (2020)
Introduction: Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In some negative phase II trials, a post-hoc NI analysis justified additional phase III trials that were successful. However, the risk
Externí odkaz:
https://doaj.org/article/9bb5f763d2cb4e348ebf7d6ca9bbebc7